-- 奧本海默公司週二發布的一份報告指出，隨著Climb Bio (CLYM) 免疫學產品線（尤其是其用於治療IgA腎病的在研療法）的預期更新，分析師對其前景更加樂觀。 奧本海默強調，對Climb Bio的抗APRIL計畫（包括CLYM116）的信心日益增強，並指出其潛在的同類最佳療效、超出預期的蛋白尿減少效果、更長的給藥間隔以及良好的安全性是關鍵的差異化優勢。 報告稱，即將公佈的皮下注射布多普魯（budoprutug）和CLYM116的臨床試驗數據可能成為關鍵催化劑，並有望驗證Climb Bio的IgA腎病變治療策略。如果結果積極，強勁的定價策略將支撐其商業成長。 奧本海默維持對該股的「跑贏大盤」評級，並將目標價從10美元上調至18美元。 Climb Bio股價週二上漲超過6%。
Price: $9.49, Change: $+0.52, Percent Change: +5.80%
Sunshine Metals (ASX:SHN) completed resource definition drilling at the Liontown gold panel, a gold-dominant deposit which is part of its Ravenswood consolidated project in Queensland, in late March, according to a Monday Australian bourse filing.The mining study and mineral resource for the Liontown project will be further updated and upgraded in May to incorporate results from the grade control drilling program.
Wanxiang Qianchao (SHE:000559) posted first-quarter attributable net profit of 246.8 million yuan, down 16% from 293.3 million yuan the previous year.Earnings per share declined to 0.074 yuan from 0.089 yuan, according to a weekend filing with the Shenzhen bourse.Operating revenue slipped 20% year over year to 2.80 billion yuan from 3.50 billion yuan.Shares of the auto parts manufacturer declined 3% in recent trade.
Eng Kah (KLSE:ENGKAH) is seeking its shareholders' approval to renew share buyback authority to purchase up to 10% of the issued shares in the company's upcoming annual general meeting, according to a Friday Malaysian bourse filing.Shares gained about 3% in Monday's afternoon trade.The manufacturer of cosmetics, personal care, household, and perfume products will share a detailed statement of the repurchase plan with shareholders in due time.